Precision Treatment in ACS-Role of Assessing Fibrinolysisopen access
- Gue, Ying X.; Jeong, Young-Hoon; Farag, Mohamed; Spinthakis, Nikolaos; Gorog, Diana A.
- Issue Date
- endogenous fibrinolysis; precision medicine; acute coronary syndrome
- JOURNAL OF CLINICAL MEDICINE, v.10, no.5
- Journal Title
- JOURNAL OF CLINICAL MEDICINE
- Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 인문대학 > 국어국문학과 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.